Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses
Natalie J. Thornburg(Oak Ridge Associated Universities), James E. Crowe(Vanderbilt University Medical Center), Gloria Fritz, Katie L. Winarski(Bipar), Jeong Hyun Lee(Scripps Research Institute), Jens Meiler(Leipzig University of Applied Sciences), Benjamin W. Spiller(Vanderbilt University), Shyam J. Deshpande, Jessica A. Belser(Centers for Disease Control and Prevention), David Blum(University of Tübingen), Gopal Sapparapu(Vanderbilt University Medical Center), Jens C. Krause(Vanderbilt University), Andrew B. Ward(Scripps Research Institute), Terrence M. Tumpey(Centers for Disease Control and Prevention), David E. Lee(Duke University), Sheng Li(University of California San Diego), D.P. Nannemann(Vanderbilt University)
Cited by 34
Related Papers
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
|Proceedings of the National Academy of Sciences|2017|1.2k
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
|Science Translational Medicine|2020|1.2k
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
|Cell Host & Microbe|2020|1.2k